PCN81 Economic Evaluation of First-LINE Atezolizumab for Extensive-STAGE SMALL-Cell LUNG Cancer: The Difference between the Standard Parametric MODEL and the Mixture Cure MODEL
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.173
https://www.valueinhealthjournal.com/article/S1098-3015(21)00390-9/fulltext
Title :
PCN81 Economic Evaluation of First-LINE Atezolizumab for Extensive-STAGE SMALL-Cell LUNG Cancer: The Difference between the Standard Parametric MODEL and the Mixture Cure MODEL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00390-9&doi=10.1016/j.jval.2021.04.173
First page :
Section Title :
Open access? :
No
Section Order :
10751